Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug

Published:2021-11 Issue: Volume:135 Page:543-555
ISSN:1742-7061
Container-title:Acta Biomaterialia
language:en
Short-container-title:Acta Biomaterialia

Author:

Shen Na,Yang Chenguang,Zhang Xuefei,Tang Zhaohui,Chen Xuesi

Funder

National Natural Science Foundation of China

Jilin Provincial Science and Technology Department

Publisher

Elsevier BV

Subject

Molecular Biology,Biomedical Engineering,Biochemistry,Biomaterials,General Medicine,Biotechnology

Reference40 articles.

1. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy;Havel;Nat. Rev. Cancer,2019

2. PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging-a literature review;Planes-Laine;Cancers,2019

3. K.-. investigators, pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N. Engl. J. Med.,2017

4. Cancer immunotherapy using checkpoint blockade;Ribas;Science,2018

5. Cellular immunotherapies for prostate cancer;McNeel;Biomed. Pharmacother.,2007

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer;International Journal of Molecular Sciences;2024-07-07

2. Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape;European Journal of Pharmaceutics and Biopharmaceutics;2024-07

3. PPIA dictates NRF2 stability to promote lung cancer progression;Nature Communications;2024-06-03

4. Cisplatin-Based Combination Therapy for Enhanced Cancer Treatment;Current Drug Targets;2024-05

5. Oxidative stress and potential effects of metal nanoparticles: A review of biocompatibility and toxicity concerns;Environmental Pollution;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3